Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + pertussis (acellular, component) vaccine (adsorbed)
- Development stage
- Unknown
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This vaccine is a trivalent combination product designed to provide active immunization against diphtheria, tetanus, and pertussis. Developed by Beijing Minhai Biotechnology, it is the first "component" DTaP vaccine produced domestically in China. Unlike traditional acellular pertussis vaccines that use co-purified antigens, this component vaccine contains individually purified and precisely quantified antigens, specifically pertussis toxoid (PT) and filamentous hemagglutinin (FHA), along with diphtheria and tetanus toxoids. The antigens are adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. It is indicated for primary and booster vaccination in infants and children to prevent infections caused by *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*.
- Brand names
- BoostrixAdacel
- Other names
- DTaP (component) vaccineDTaP-cp vaccineadsorbed acellular diphtheria, tetanus and pertussis (component) combined vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria + tetanus + pertussis (acellular, component) vaccine (adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + pertussis (acellular, component) vaccine (adsorbed).